Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 100 versus LAZANDA.
Head-to-head clinical analysis: DURAGESIC 100 versus LAZANDA.
DURAGESIC-100 vs LAZANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pure opioid agonist that binds to mu-opioid receptors in the CNS, mimicking endogenous endorphins to inhibit pain transmission. Also interacts with kappa and delta receptors. Therapeutic effects include analgesia, sedation, and euphoria.
Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein-coupled receptors to inhibit adenylate cyclase, reduce cAMP production, and modulate ion channels, leading to decreased neurotransmitter release (e.g., substance P, glutamate) and hyperpolarization of neurons, resulting in analgesia and sedation.
Transdermal patch; initial dose based on prior opioid use: for opioid-naive patients, 12 mcg/h every 72 hours; for opioid-tolerant patients, convert using equianalgesic tables; maximum dose 100 mcg/h per patch; apply to non-irritated, non-irradiated skin on chest, back, flank, or upper arm.
100 mcg (one spray) intranasally as needed for breakthrough pain; may repeat once after 15-30 minutes if needed; do not exceed 2 doses per episode and 4 doses per day.
None Documented
None Documented
Terminal elimination half-life approximately 20–27 hours after transdermal system removal (range 13–25 hours in healthy adults; prolonged in elderly, hepatic impairment, and cachexia).
Terminal elimination half-life: 6–10 hours (mean approximately 7 hours) following nasal administration; prolonged in hepatic impairment.
Renal (primarily as metabolites, <10% unchanged fentanyl); fecal (about 9% of dose).
Renal excretion of metabolites (mostly fentanyl metabolites, primarily norfentanyl): approximately 75%; fecal excretion: approximately 9%; less than 10% excreted as unchanged fentanyl in urine.
Category C
Category C
Opioid Analgesic
Opioid Analgesic